Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort Study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-190X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort Study ; volume:34 ; number:3 ; day:26 ; month:2 ; year:2020 ; pages:395-404 ; date:6.2020
BioDrugs ; 34, Heft 3 (26.2.2020), 395-404, 6.2020
- Creator
-
Ho, Stephanie L.
Niu, Fang
Pola, Suresh
Velayos, Fernando S.
Ning, Xian
Hui, Rita L.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40259-020-00409-y
- URN
-
urn:nbn:de:101:1-2020071622084380268594
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 14.08.2025, 10:59 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ho, Stephanie L.
- Niu, Fang
- Pola, Suresh
- Velayos, Fernando S.
- Ning, Xian
- Hui, Rita L.
- SpringerLink (Online service)
Other Objects (12)
Correction to: Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort Study
Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis
Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab
PF-06438179/GP1111: An Infliximab Biosimilar
Infliximab-induced hot kidneys on bone scintigraphy
Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study
Bestimmung von Infliximab und Anti-Infliximab-Antikörpern im Rahmen des Therapeutischen Drug- und Immunogenitäts-Monitoring bei chronisch entzündlichen Darmerkrankungen
Antikörper gegen Remicade-Infliximab reagieren auch bei Biosimilars
Exposure to Infliximab During Pregnancy: Post-Marketing Experience
Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
Hodgkin's Lymphoma in Crohn's Disease Treated with Infliximab
Correction to: Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort Study
Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis
Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab
PF-06438179/GP1111: An Infliximab Biosimilar
Infliximab-induced hot kidneys on bone scintigraphy
Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study
Bestimmung von Infliximab und Anti-Infliximab-Antikörpern im Rahmen des Therapeutischen Drug- und Immunogenitäts-Monitoring bei chronisch entzündlichen Darmerkrankungen
Antikörper gegen Remicade-Infliximab reagieren auch bei Biosimilars
Exposure to Infliximab During Pregnancy: Post-Marketing Experience
Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
Hodgkin's Lymphoma in Crohn's Disease Treated with Infliximab
Correction to: Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort Study
Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis
Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab
PF-06438179/GP1111: An Infliximab Biosimilar
Infliximab-induced hot kidneys on bone scintigraphy
Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study
Bestimmung von Infliximab und Anti-Infliximab-Antikörpern im Rahmen des Therapeutischen Drug- und Immunogenitäts-Monitoring bei chronisch entzündlichen Darmerkrankungen
Antikörper gegen Remicade-Infliximab reagieren auch bei Biosimilars
Exposure to Infliximab During Pregnancy: Post-Marketing Experience
Correction to: PF-06438179/GP1111: An Infliximab Biosimilar